Study links high serum enzyme to liver cancer:
This article was originally published in Clinica
Executive Summary
Measuring the level of an enzyme in serum could help doctors identify which patients with hepatitis C virus-associated cirrhosis are at risk of rapidly developing liver cancer, according to a Japanese team. A seven-year follow-up study, published in Cancer (August 15), showed that the five-year incidence rate of hepatocellular carcinoma was 53.6% in patients with persistently high levels of the enzyme alanine aminotransferase (ALT) compared with 7.1% in those with persistently low levels of the enzyme. The team suggested that patients with high serum ALT levels may benefit from intensive surveillance using medical imaging.
You may also be interested in...
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.
GE HealthCare Launches AI-Powered Voluson Ultrasound For Women’s Health
Voluson Signature 20 and 18 ultrasound provides clinicians with workflow efficiencies in detecting female reproductive health problems, especially those related to pregnancy.
CDER, CBER Not Seeing Hiring Slowdown Despite US FDA Warnings
FDA officials have said hiring could be slowed if an inflationary pay increase is not included in the agency budget, but CDER and CBER continue to add staff at a steady pace.